RCC cells transfected with DDX11 siRNA or control siRNA were treated with a clinically approved PARP inhibitor, olaparib; subsequently, immunofluorescence staining of PARP was performed to measure and investigate the increased PARP expression in nuclei of DDX11 knockdown RCC cells. The gene discussed is PARP1; the disease is renal cell carcinoma.